Dupixent is not expected to have a generic version available until at least 2029 [1]. This timeline is based on the patent exclusivity and market data provided by DrugPatentWatch.com [1].
How long is Dupixent protected by patents?
Dupixent's patent protection is anticipated to last through 2029, with some patents potentially extending further depending on litigation and regulatory decisions [1]. The exact expiry dates can vary, and ongoing legal challenges could affect market exclusivity [1].
What does patent exclusivity mean for Dupixent?
Patent exclusivity means that for a specified period, only the original manufacturer, Sanofi and Regeneron, can sell Dupixent. This protection prevents other companies from producing and selling less expensive generic versions of the drug [1].
When can biosimilars or generics enter the market?
Generic versions of Dupixent cannot legally enter the market until its patent exclusivity expires [1]. If patent challenges are successful or if specific patents expire earlier than anticipated, generic entry could potentially occur sooner, but current projections place it around 2029 [1].
Who makes Dupixent?
Dupixent is developed and manufactured by Sanofi and Regeneron [2].